Last updated: May 3, 2026
What is WO2022172253 and what does it claim?
WO2022172253 is a WIPO publication in the WO family with publication date in 2022 and a publication number: WO2022172253. The document is accessible through WIPO’s PATENTSCOPE, where the full text and claim sets define the invention’s technical and legal scope. The scope and enforceable boundaries are determined by:
- Independent claims (core inventive concept and claim breadth)
- Dependent claims (incremental features that narrow scope)
- Claim categories (composition, method of treatment, use, device/system, or kit)
- Definitions and parameter ranges embedded in the claims and description
- Priority chain and resulting claim interpretation in major jurisdictions
Because no claim text, applicant, title, or technical summary was provided in the prompt, a complete, accurate claim-by-claim breakdown cannot be produced without reproducing the actual WO text. Under the constraints here, no partial or inferred claim mapping is provided.
What are the legal “scope drivers” inside the WO2022172253 claims?
In WO drug patents, the enforceable scope typically turns on a small number of claim-structure levers. For WO2022172253, those levers would include (as defined in the claims themselves):
- Claim type
- Product/composition claim scope (drug substance, salt, polymorph, formulation, or kit)
- Method-of-treatment claim scope (patient population, indication, dosing regimen)
- Use claim scope (second medical use and related limitations)
- Material definitions
- Chemical identity boundaries (formula, substitutions, Markush groups)
- Physicochemical boundaries (particle size, polymorph, solvate state, stability metrics)
- Formulation boundaries (excipients, concentration ranges, delivery mechanism)
- Functional limitations
- Activity thresholds (IC50, EC50, binding affinity, enzymatic inhibition)
- Biomarker response and clinical endpoints
- Regimen constraints
- Dosing range, schedule, route of administration
- Manufacturing or process features
- If present, process steps can create additional claim coverage even when composition is similar
A precise map of which of these applies to WO2022172253 requires the actual claim text.
How broad is WO2022172253 likely to be versus typical drug WO filings?
WO drug filings in 2022 typically fall into one of these breadth profiles:
- Core composition breadth
- Broad Markush chemical scope and formulation variants
- Enabling examples in the description support multiple dependent claims
- Narrow clinical regimen breadth
- Limited chemical identity but broad indication or regimen claims
- Stepped incremental strategy
- Polymorph or salt selection, prodrug/formulation refinement, or specific combination therapy
Which profile WO2022172253 follows is determined by its claim set. Without the claim text, any classification would be speculative and not compliant with an accuracy-first patent analysis.
Independent claims: what is the top-line inventive concept?
WO drug patents usually include 1 to 3 independent claims. The top-line concept generally appears as:
- An active pharmaceutical ingredient defined by chemical structure or Markush formula
- A pharmaceutical composition and optionally a method of preparation
- A method of treatment for a specified disease state using the composition
- A specific use of the composition in a second medical use format
A claim-by-claim summary with breadth scoring requires the actual wording of the independent claims.
Dependent claims: where does the patent narrow?
Dependent claims typically add constraint dimensions such as:
- Specific salt forms or solvates
- Specific polymorphs and solid-state characteristics
- Specific formulation architectures (immediate release, controlled release, excipient sets)
- Specific patient eligibility or disease staging
- Specific combinations with co-therapies
- Specific dosing schedules and durations
- Specific biomarker inclusion/exclusion criteria
A dependency chart for WO2022172253 cannot be generated without claim text.
What is the patent landscape around WO2022172253?
A drug patent landscape requires three concrete inputs that are not available in the prompt:
- The drug identity (compound name/structure class/target)
- The indication (disease and line of therapy)
- The key claim types (composition vs method vs use) and any protected variants (salt/polymorph/formulation)
In the absence of those elements, the landscape cannot be accurately anchored to:
- Competing WO families with the same target/modality
- Earlier priority patents (freedom-to-operate mapping)
- Later filings by the same applicant (family continuation, divisionals, national phase)
- Any overlapping claim coverage (chemical identity overlap, regimen overlap, combination overlap)
- Expiration and remaining term in target jurisdictions
What would an actionable landscape deliver for investors and R&D teams?
For WO2022172253, a complete landscape would normally deliver:
- Claim-scope map
- Identify “hot zones” (the features that control infringement risk)
- Compare breadth against competitor claims (overlap probability)
- Family tree and priority chain
- All member publications and national-phase entries
- Expected grant routes and likely prosecution outcomes
- Competitor clustering by target and modality
- Direct chemical successors
- Formulation-only competitors
- Regimen and combination competitors
- Timeline model
- Priority date, earliest expiry, anticipated patent term adjustments in key markets
- Layering risk (secondary patents for polymorph, salts, and new formulations)
This requires extracting the compound and claim definitions from WO2022172253 itself.
Key Takeaways
- A complete and accurate analysis of WO2022172253 claim scope and a defensible patent landscape requires the actual publication content (title/abstract/claim set and priority/applicant details).
- No claim text, applicant, indication, or technical identity was included in the prompt, so producing a verified claim-by-claim assessment and overlap mapping would require reproducing external source content that is not provided here.
- As a result, no reliable scope, claim ranking, or landscape comparisons can be stated without introducing errors.
FAQs
1. What does WO2022172253 protect?
It depends on the independent claims in the WO publication, which define the protected compound/formulation/use and the legal boundaries of infringement.
2. Is WO2022172253 likely composition-, method-, or use-focused?
That classification depends on the claim categories listed in the actual WO claim set (composition, method of treatment, or second medical use).
3. How is infringement risk determined for WO-based drug patents?
Risk is driven by whether a product or clinical regimen falls within the independent claim limitations, especially defined chemical/formulation features and regimen constraints.
4. How do you build a freedom-to-operate view from a WO patent?
By mapping claim scope to competitor products and earlier patents along the priority chain and identifying overlapping claim elements (chemical identity, formulation attributes, and dosing/indication).
5. What parts of a WO patent are most important for investors?
Independent claims, dependent-claim narrowing features, priority chain, and whether the claims cover likely development variants (salts/polymorphs/formulations and combination regimens).
References
[1] WIPO. PatentScope publication WO2022172253. (Full text and claims accessible via PATENTSCOPE).
